Arizona State Retirement System purchased a new position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 11,853 shares of the company's stock, valued at approximately $340,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of CG Oncology by 73.0% during the third quarter. State Street Corp now owns 1,700,653 shares of the company's stock valued at $64,166,000 after acquiring an additional 717,722 shares in the last quarter. Janus Henderson Group PLC increased its stake in CG Oncology by 7.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,526,534 shares of the company's stock valued at $57,596,000 after purchasing an additional 99,517 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of CG Oncology by 8.9% during the third quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company's stock valued at $46,157,000 after buying an additional 100,106 shares during the last quarter. Geode Capital Management LLC increased its position in shares of CG Oncology by 96.2% during the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock worth $40,701,000 after acquiring an additional 528,749 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in shares of CG Oncology by 575.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 746,063 shares of the company's stock worth $28,149,000 after acquiring an additional 635,653 shares during the last quarter. Institutional investors own 26.56% of the company's stock.
Analyst Ratings Changes
A number of analysts have commented on the company. HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a report on Friday, January 10th. Morgan Stanley reissued an "overweight" rating and issued a $55.00 price target on shares of CG Oncology in a research report on Friday, March 7th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $66.00 price objective on shares of CG Oncology in a report on Friday, December 6th. Finally, TD Cowen started coverage on shares of CG Oncology in a report on Tuesday, January 7th. They issued a "buy" rating for the company. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, CG Oncology presently has a consensus rating of "Buy" and an average price target of $63.88.
Check Out Our Latest Stock Report on CG Oncology
Insider Buying and Selling at CG Oncology
In related news, Director Leonard E. Post sold 1,000 shares of the company's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
CG Oncology Price Performance
CGON traded up $0.53 during trading on Wednesday, hitting $28.01. 467,322 shares of the company traded hands, compared to its average volume of 627,953. CG Oncology, Inc. has a one year low of $23.91 and a one year high of $46.99. The stock's fifty day moving average is $28.25 and its 200 day moving average is $32.33.
About CG Oncology
(
Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Read More
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
